Ublituximab Added to Ibrutinib Demonstrates ORR Benefit for Relapsed/Refractory CLL

Retrieved on: 2021-03-09 23:03:45

Tags for this article:

Click the tags to see associated articles and topics

Ublituximab Added to Ibrutinib Demonstrates ORR Benefit for Relapsed/Refractory CLL. View article details on hiswai:

Excerpt

The phase 3 study evaluated the glycoengineered anti-CD20 monoclonal antibody in combination with the Bruton's tyrosine kinase (BTK) inhibitor, ...

Article found on: www.targetedonc.com